Abstract
In the present study, the effect of immunophenotyping on the prognoses of patients with multiple myeloma (MM) treated with bortezomib plus dexamethasone was investigated. The study involved 46 patients with MM, and analyzed the prognostic significance of the expression of cluster of differentiation (CD)45, CD56 and mature plasma cell (MPC)-1, and other factors including the International Staging System (ISS) stage, age, gender, the immunoglobulin subtype and the treatment line number prior to bortezomib treatment. Although CD56 and MPC-1 expression did not appear to affect the time to next treatment (TNT) or overall survival rate (OS), the univariate analysis determined that CD45 positivity was an adverse prognostic factor for TNT and OS, and that being male was significantly associated with inferior TNT and OS. Multivariate analyses determined that CD45 expression was prognostically significant for TNT and OS. In conclusion, CD45 positivity is an adverse prognostic factor in MM patients treated with bortezomib. The data from the present study demonstrate the clinical importance of classifying MM cells immunophenotypically to determine the prognoses of patients.
References
Jun 1, 1995·International Journal of Hematology·M M KawanoA Kuramoto
May 8, 1999·British Journal of Haematology·R FujiiM M Kawano
May 10, 2001·International Journal of Hematology·W J Leonard
Mar 6, 2002·Blood·Hideaki IshikawaMichio M Kawano
Jun 13, 2002·British Journal of Haematology·Naohi SaharaRyuzo Ohno
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Apr 6, 2004·Leukemia & Lymphoma·Naohi Sahara, Akihiro Takeshita
May 26, 2005·International Journal of Hematology·Yoshiaki KurodaAkiro Kimura
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Jun 17, 2005·Leukemia·S KumarT E Witzig
Dec 3, 2005·Leukemia & Lymphoma·Hong ChangQi Long Yi
Jan 31, 2006·International Journal of Hematology·Ken-ichiro OtsuyamaMichio M Kawano
Sep 26, 2006·Leukemia Research·Hong ChangDonna Reece
Nov 11, 2006·Leukemia·V SagasterJ Drach
Nov 11, 2006·Leukemia·S JagannathK C Anderson
Sep 25, 2007·Bone Marrow Transplantation·M HundemerH Goldschmidt
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauJean-Luc Harousseau
Sep 11, 2012·Hematological Oncology·Dimitrios MaltezasMarie-Christine Kyrtsonis
Dec 5, 2012·Bone Marrow Transplantation·Y Kanda
Mar 6, 2013·European Journal of Pharmacology·Ines TagougCharles Dumontet
Jul 3, 2013·Leukemia Research·Noriyoshi IriyamaTomoki Naoe
Jul 3, 2013·Leukemia Research·Daryl TanJae Hoon Lee
Jan 21, 2014·Annals of Hematology·Noriyoshi IriyamaTomoki Naoe
Mar 4, 2014·International Journal of Hematology·Junya KurodaUNKNOWN Kansai Myeloma Forum Investigators
Jul 6, 2014·Leukemia·R BrownD Joshua
Citations
Sep 19, 2019·Journal of Clinical Pharmacy and Therapeutics·Satoko OkaMasaharu Nohgawa
Jul 26, 2019·Medical Oncology·Kazuya KuriharaMasami Takei
Jul 10, 2021·PloS One·Akiko YamadaAkihiko Gotoh
Aug 6, 2021·Pathology, Research and Practice·Epameinondas KoumpisEleftheria Hatzimichael
Aug 5, 2021·Cancer Investigation·Nadia ElMenshawyMohamed Eissa